DoMore Diagnostics and Erasmus MC Cancer Institute Announce Collaboration to Validate Digital Biomarker Histotype Px® Colorectal for Personalized Cancer Treatment in Rectal Cancer Patients
OSLO – November 11, 2024 – DoMore Diagnostics, a leader in AI and deep learning precision medicine for cancer, and Erasmus MC Cancer Institute, Rotterdam, a major academic and clinical research center in oncology, announce a research collaboration to clinically validate Histotype Px® Colorectal (Histotype Px) as a biomarker in large patient cohorts of up to 2200 stage II and stage III rectal cancer patients.
This study includes patients from the Snapshot rectum 2011 and 2016 cohorts not treated with adjuvant chemotherapy (ACT) after resection of the primary tumor. The objective is to document the performance of Histotype Px and generate evidence that can support clinical guideline inclusion and adoption of Histotype Px as a digital biomarker to guide ACT treatment decisions post-surgery in rectal cancer patients.
Professor Dr. Cornelis Verhoef and Head of Oncologic and Gastrointestinal Surgery at Erasmus MC, a renowned expert in the field of rectal cancer, and Principal Investigator, said:
“There is a high medical need for biomarkers that can guide better and personalized treatment decisions. Adjuvant chemotherapy after curative resection is not standard of care for rectal cancer patients in The Netherlands and this results in a unique database worldwide. The objective of this study is to test the performance of Histotype Px as a digital biomarker in non-treated patients and its potential use as a clinical decision support tool for selecting rectal cancer patients with poor prognosis who might benefit from ACT.” With the help of Mirthe Ubink, MD and PhD candidate focusing on predictive markers in rectal cancer, the team will collect and prepare all patient data and histological material for the analysis.
Torbjørn Furuseth, MD, CEO and Co-Founder of DoMore Diagnostics added:
“We are delighted to be partnering with pioneering clinicians and researchers from a leading cancer center in the Netherlands to validate Histotype Px in a unique cohort of rectal cancer patients who did not receive adjuvant chemotherapy post-surgery. This study is an important step in documenting the performance of Histotype Px as a digital biomarker to guide clinical decision making. A successful outcome could help identify high risk patients who are likely to benefit from ACT and low risk patients who are better off without ACT. Our partnership with Erasmus MC represents another significant milestone on our path towards clinical guideline inclusion of Histotype Px and its widespread use as a clinical decision support tool to improve outcomes in colorectal cancer patients.”
A prestigious private-public IPN grant has been awarded to DoMore Diagnostics from The Research Council of Norway to support this research collaboration.
About Erasmus MC Cancer Institute
At Erasmus MC Cancer Institute, located in the heart of Rotterdam, specialists work closely with patients to fight cancer. With over 100 years of experience, the institute has gained extensive expertise in diagnosing and treating cancer. By using the latest technologies and treatments, they maximize the chances of finding a cure. For every type of cancer, specialists collaborate to deliver personalized, high-quality care. Researchers at the institute work tirelessly every day to improve the quality of cancer care, with groundbreaking studies that pave the way for new and promising treatments.
For further information: Erasmus MC, Facebook, LinkedIn, Instagram, X
About DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Its unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.
About Colorectal Cancer and Histotype Px® Colorectal
Colorectal cancer is the third most common and second most deadly cancer but has seen little innovation in diagnostics and treatment in the last decades. Adjuvant chemotherapy (ACT) may be provided after primary surgery to prevent the disease from recurring, however overtreatment is prevalent with up to 85% of patients with stage II and stage III not benefiting from ACT and only suffering side effects.
Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, identifying patients who may or may not benefit from adjuvant chemotherapy. Data previously published in The Lancet and Lancet Oncology showed the test can accurately predict survival outcomes in colorectal cancer patients. Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.
For more information about the Histotype Px Colorectal biomarker, please visit:
www.domorediagnostics.com
LinkedIn
The Lancet publication
The Lancet Oncology publication
Contact:
Torbjørn Furuseth, MD
torbjorn.furuseth@domorediagnostics.com